H.C. Wainwright & Co.

InMed Pharmaceuticals Secures $6M Via Private Placement

Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings

Advertising, Acquisition And Potential Subscription Model Point To $6PT For Super League Gaming

InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings

Advertising, Acquisition And Potential Subscription Model Point To $6PT For Super League Gaming

'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis

Alzheon's IPO: What You Need To Know

H.C. Wainwright & Co. Recent News

Analyst: Biofuel Company Gevo Could More Than Quadruple Revenue By 2025

What You Should Know About The Drug Approval Valeant Could Receive This Week

Do Any Signs Of Life Remain In OnceMed's Demcizumab Development?

Where Does Anthera Go From Here?

H.C. Wainwright Is Bullish On Cara Therapeutics Shares

Galectin Shares Downgraded As NASH-FX Failure Likely Degrades The Prognosis For NASH-CX

H.C. Wainwright Initiates Mirna At Buy, Sees 135% Upside

H.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics

H.C. Wainwright Downgrades United Therapeutics To Neutral

Cardiome Is A 'Rising Global Spec Pharma Play With Growth Potential'

H.C. Wainwright Initiates Radius Health At Buy, $55 Target

HC Wainwright Upgrades Caladrius Biosciences To Buy, Sets $1.25 Price Target

H.C. Wainwright Triples Celator Valuation, Says Latest Trial Win Is Rare

H.C. Wainwright Still Buying Amarin, Sees DMC Decision By Summer

Biocept Could Double On Liquid Biopsy Leadership: H.C. Wainwright

What's Happening At The ASCO Conference?

H.C. Wainwright Initiates Coverage On Celladon, Cites Impressive Trial Results For Heart Failure Therapy

H.C. Wainwright & Co. Retains Positive Outlook On OXiGENE

UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside

UPDATE: H.C. Wainwright & Co. Initiates Coverage On Finjan Holdings, Inc. On Multiple Positive Factors

UPDATE: H.C. Wainwright & Co. Initiates Coverage On PolyMet Mining Corp. (USA) On Large-Scale Minnesota Project

Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation

UPDATE: H.C. Wainwright & Co. Initiates Coverage On MELA Sciences On Commercialization Strategy Change